Uploaded January 2025 | Updated September 2026, 2 weeks ago
We recognise that gene therapy developers still face major challenges in achieving sufficiently high quality, high yield processes.
To further reduce the cost of goods associated with viral vector manufacture, in particular with AAV bioprocessing, we are increasingly focusing our R&D in improving the performance of specific unit operations, including improved cell line performance, plasmid design-based solutions, purification and scale.
Learn more about our viral vector capabilities ➡️ ct.catapult.org.uk/how-we-work/challenge-themes#driving-efficiency-of-adeno-associated-virus-aav-production
We recognise that gene therapy developers still face major challenges in achieving sufficiently high quality, high yield processes.
To further reduce the cost of goods associated with viral vector manufacture, in particular with AAV bioprocessing, we are increasingly focusing our R&D in improving the performance of specific unit operations, including improved cell line performance, plasmid design-based solutions, purification and scale.
Learn more about our viral vector capabilities ➡️ ct.catapult.org.uk/how-we-work/challenge-themes#driving-efficiency-of-adeno-associated-virus-aav-production
